PLUVICTO, also known as lutetium Lu‑177 vipivotide tetraxetan, invites viewers to learn more about the radioligand therapy for advanced prostate cancer, in its latest commercial.

“What do you do when things get tough? You don’t give up. If you’ve been diagnosed with metastatic prostate cancer and have tried hormone therapy, ask your doctor about Pluvicto. Pluvicto is not chemotherapy. It’s a different treatment that targets PSMA positive cells. It’s now FDA approved after one hormone therapy and before chemotherapy.
Pluvicto involves contact with radioactivity, which may increase the risk for cancer and cause fetal harm. Drink plenty of fluids, urinate often, use contraception, and talk to your doctor about ways to reduce the risk of exposing others to radiation during and after treatment,” the voiceover says in the 60-second spot.

PLUVICTO combines a PSMA-targeting ligand (PSMA-617) with the beta-emitting radioisotope lutetium‑177, and it’s the first and only FDA-approved targeted radiopharmaceutical designed for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).